TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04833829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHIMES Intervention
Description: There are six components to the intervention:~1. Posters and other print materials to prompt providers and patients to discuss MH care engagement.~2. Brief verbal scripts to help HIV providers facilitate patient MH engagement and discuss barriers to MH utilization.~3. Expanded MH screening procedures, including at initial intake.~4. Case management, emphasizing MH care engagement.~5. Interactive trainings for all HIV providers on MH needs, screening/treatment, and barriers to MH service utilization specific to YB-GBMSM.~6. Regular case review meetings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHIMES Intervention
Description: There are six components to the intervention:~1. Posters and other print materials to prompt providers and patients to discuss MH care engagement.~2. Brief verbal scripts to help HIV providers facilitate patient MH engagement and discuss barriers to MH utilization.~3. Expanded MH screening procedures, including at initial intake.~4. Case management, emphasizing MH care engagement.~5. Interactive trainings for all HIV providers on MH needs, screening/treatment, and barriers to MH service utilization specific to YB-GBMSM.~6. Regular case review meetings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The standard of care practices of referring patients to mental health services of the clinic during Months 1 - 12 of the study.
Study: NCT02476760

Intervention type: DRUG
Intervention: Biguanides
Description: Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.

Intervention type: DRUG
Intervention: Sulfonylureas
Description: Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.

Intervention type: DRUG
Intervention: Sulfonylureas
Description: Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Study: NCT04410692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prediction Market
Description: Participants bet on likely future outcomes using a prediction market
Study: NCT03455075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethandrolone-Undecanoate
Description: Single doses of DMAU in castor oil/benzyl benzoate administered in 100 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethandrolone-Undecanoate
Description: Single doses of DMAU in castor oil/benzyl benzoate administered in 100 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethandrolone-Undecanoate
Description: Single doses of DMAU in castor oil/benzyl benzoate administered in 100 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethandrolone-Undecanoate
Description: Single doses of DMAU in castor oil/benzyl benzoate administered in 100 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 0.03 MG
Description: Single doses of LNG administered in 30 mcg capsules.
Study: NCT02476760

Intervention type: DRUG
Intervention: Thiazolidinediones
Description: Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.

Intervention type: DRUG
Intervention: Thiazolidinediones
Description: Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.

Intervention type: DRUG
Intervention: Alpha-glucosidase inhibitors
Description: Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Study: NCT03455075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 0.03 MG
Description: Single doses of LNG administered in 30 mcg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo capsules that look like DMAU and LNG capsules but with no active ingredients.
Study: NCT02476760

Intervention type: DRUG
Intervention: Alpha-glucosidase inhibitors
Description: Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.

Intervention type: DRUG
Intervention: Meglitinides
Description: Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event) day.

Intervention type: DRUG
Intervention: Meglitinides
Description: Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event) day.
Study: NCT03820999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral and written information on tick-bites and Lyme disease
Description: See under study arm descriptions
Study: NCT00390949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer education among commercial sex workers and clients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condom distribution and promotion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Syndromic treatment of sexually transmitted infections

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systemic counselling for STI patients
Study: NCT03076528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensor-based interactive exercise (game-based exercise)
Description: This intervention includes interactive game-based lower extremity training including repetitive ankle movements in multiple directions. Wearable sensors will provide real-time feedback from foot and ankle position and allow perception of motor-errors during each motor-action

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-technology foot and ankle exercise program
Description: Subjects are asked to perform non-technology based foot and ankle exercises, which include plantar flexion and extension.
Study: NCT02585973

Intervention type: DRUG
Group type: OTHER
Intervention: AZD1775
Description: AZD1775 given twice daily (BID) for three consecutive days (M-W) concomitantly with standard of care cisplatin and radiation. AZD1775 doses will be escalated in 50 mg increments up to 200 mg BID (M-W) in subsequent cohorts to determine the MTD.

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: 40 mg/m2 IV infused over 1 hour D1 of each week of radiation

Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity Modulated Radiotherapy Treatments
Description: Total dose will be 70 Gy at 2Gy/fx, 35 fractions, M to Fri, for 7 weeks
Study: NCT03628001

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ERCP
Description: Pts will be randomized with or without sphinterectomy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ERCP
Description: Pts will be randomized with or without sphinterectomy.
Study: NCT01483612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary lifestyle intervention
Description: Individual meetings with a dietitian and a kinesiologist at 0, 3, 6 weeks and then every 6 weeks for 18 months or until delivery. A reminder phone call/email will also take place once between each meeting.~The program also includes 12 group sessions discussing subjects about nutrition, psychology and demonstration of physical activity.
Study: NCT03455075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo capsules that look like DMAU and LNG capsules but with no active ingredients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsules that look like DMAU and LNG capsules but with no active ingredients.
Study: NCT04793932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PAXG
Description: Nab-paclitaxel, cisplatin and gemcitabine drugs will be administered on day 1 and 15 every 28 days. Capecitabine tablets will be taken orally on days 1 to 28, every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFIRINOX
Description: Oxaliplatin, folinic acid, irinotecan and 5-Fluoruracil will be administered on day 1 and 15 every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: short-course chemotherapy
Description: other two months of chemotherapy after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: long-course chemotherapy
Description: other two months of chemotherapy before surgery
Study: NCT04902261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200 mg every three weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: Nab-paclitaxel 125mg/m2 on d1 and d8 every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel 125mg/m2 on d1 and d8 every three weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 on d1 and d8 every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 on d1 and d8 every three weeks
Study: NCT02963909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IXIARO
Description: An inactivated vaccine indicated for active immunization for the prevention of disease caused by Japanese encephalitis virus (JEV).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride 5 mcg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride 5 mcg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride 5 mcg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YF Vax 17D Strain
Description: A stabilised Yellow Fever Vaccine (Live) that is an injectable suspension of the attenuated 17D strain of yellow fever virus. The vaccine is injected by the subcutaneous route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zika Virus Purified Inactivated Vaccine (ZPIV)
Description: Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zika Virus Purified Inactivated Vaccine (ZPIV)
Description: Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zika Virus Purified Inactivated Vaccine (ZPIV)
Description: Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
Study: NCT04404816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heliox
Description: NIV-NAVA with a conventional gas mixture (air-oxygen) at baseline, 3 hours of NIV-NAVA with heliox and return to NIV-NAVA with air-oxygen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heliox
Description: NIV-NAVA with a conventional gas mixture (air-oxygen) at baseline, 3 hours of NIV-NAVA with heliox and return to NIV-NAVA with air-oxygen.
Study: NCT02028156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partially Hydrolyzed Infant Formula
Description: Commercially available infant formula
Study: NCT01542684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine
Description: Starting dose: 40 mg/m\^2 intravenously (IV) or subcutaneously (SQ) daily for 4 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 mcg/m\^2 IV or SQ one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.
Study: NCT03978897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction tourniquet
Description: A blood flow restriction tourniquet, which impedes arterial flow to extremity at 50% of usual flow.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evidence based physical/occupational therapy
Description: Up to date physical/occupational therapy for lateral epicondylitis
Study: NCT02998515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Companion (Liquid oxygen device)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Companion (Liquid oxygen device)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activox (concentrator)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activox (concentrator)
Study: NCT06566105

Intervention type: GENETIC
Group type: OTHER
Intervention: precision medicine approach
Description: precision medicine approach to improvement of risk stratification of hepatic and cardiovascular complications in non-alcoholic fatty liver disease in a group of healthy subjects at increased risk of metabolic pathologies
Study: NCT03358732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endometrial navigation one day before the embyo transfer using IUI catheter ,
Description: one day before the actual ET, the participants, in the study group, were taken into the operating room with a moderately full bladder at 10 am. The patient was placed in the lithotomy position and a sterile speculum was inserted into the vagina. The cervix was cleaned with sterile swabs and sterile water, and a mock transfer was performed using a soft catheter (Wallace Intrauterine Insemination Catheter; Sims Portex Ltd., Hythe, Kent, UK). The catheter has an outer sheet with memory , to aid insertion, and a soft inner catheter with atraumatic tip. Under ultrasound guidance, only the soft inner catheter was introduced beyond the internal cervical os till it was 0.5 cm from the fundus. It was, then, gently withdrawn out of the uterus, and the speculum was removed.
Study: NCT01106352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel (75 mg/m\^2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m\^2 is allowed as per the approved docetaxel label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (75 mg/m\^2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m\^2 is allowed as per the approved docetaxel label.
Study: NCT01315054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMT provider dosage training
Description: Training on methadone dosing provided to health care providers working in methadone maintenance clinics

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMT provider dosage training
Description: Training on methadone dosing provided to health care providers working in methadone maintenance clinics

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: targeted counseling
Description: targeted counseling provided to methadone maintenance clinic attendees

Intervention type: OTHER
Group type: OTHER
Intervention: national guidelines
Description: Provided a hard copy of the existing national guidelines for methadone dosing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: national guidelines
Description: Provided a hard copy of the existing national guidelines for methadone dosing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: national guidelines
Description: Provided a hard copy of the existing national guidelines for methadone dosing
Study: NCT01890109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered via subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via subcutaneous injection
Study: NCT00354731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxifylline
Description: Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
Study: NCT02026102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICD Decision Aid Toolkit
Description: Research assistants will provide patients with a toolkit of decision aids. Participants will have the option of using all of the decision aids or just some of the decision aids.
Study: NCT01403428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation
Description: Noninvasive positive pressure ventilation (NPPV) will deliver pressurized gas through a nasal or oronasal mask, connected to a pressure targeted ventilator. NPPV provides ventilator support without the use of an endotracheal tube. Standard of care includes use of corticosteroids, oxygen, short acting β-agonist and inhaled ipratropium bromide.
Study: NCT01286207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rizatriptan 5 mg
Description: Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Description: Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Active standard care
Study: NCT01307631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03563235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xulin Jiangu granules
Description: Xulin Jiangu granules tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xulin Jiangu granules
Description: Xulin Jiangu granules tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol capsules
Description: Calcitriol capsules tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol capsules
Description: Calcitriol capsules tablets
Study: NCT02139579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg every 3 weeks
Study: NCT01333631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: Valproic acid given concurrent with chemoradiotherapy for patients with pancreatic cancer
Study: NCT01855100

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Starting dose (3 weeks): 15 mg BID, then 15 mg OD or 20 mg OD.
Study: NCT02179931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flupentixol/melitracen film-coated tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Flupentixol/melitracen coated tablet (Deanxit®)
Study: NCT01174368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cancer Macrobead placement in abdominal cavity
Description: 8 macrobeads per kilogram
Study: NCT02076230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] TH-302 (Label 1)
Description: \[14C\]-labeled TH-302 (Label 1) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] TH-302 (Label 2)
Description: \[14C\]-labeled TH-302 (Label 2) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unlabeled TH-302
Description: Unlabeled TH-302 will be administered along with labeled TH-302 at the dose of 340 milligram per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Day 1 of Part A, followed by recommended Phase 2 dose (RP2D) of 480 mg/m\^2 as monotherapy infusion over 30 minutes on Days 8 and 15 of Part A; and on Days 1, 8 and 15 of Part B, until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow up, or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unlabeled TH-302
Description: Unlabeled TH-302 will be administered along with labeled TH-302 at the dose of 340 milligram per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Day 1 of Part A, followed by recommended Phase 2 dose (RP2D) of 480 mg/m\^2 as monotherapy infusion over 30 minutes on Days 8 and 15 of Part A; and on Days 1, 8 and 15 of Part B, until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow up, or death.
Study: NCT01839565

Intervention type: DEVICE
Intervention: Quadrilateral Surface Plate
Description: Patients with acetabular fracture surgically treated using the Quadrilateral Surface Plate
Study: NCT06635239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-creation and assessment
Description: 1. MOOC co-creation: development of a MOOC initially structured into modules consisting of a variety of downloadable educational resources such as videos, audios, infographics, texts, etc., covering several units related to Person-Centered Care (Shared Decision-Making, strategies for managing the clinical encounter, Patient Decision Aids, etc.) and Digital Health Literacy (skills, tools, etc.). These resources will serve as the central focus of the educational intervention, and may undergo appropriate adjustments established during the co-creation sessions.~2. MOOC acceptability and effectiveness: evaluation of the MOOC in terms of effectiveness (level of Health Literacy, Digital Health Literacy, and knowledge acquired) and acceptability (usability, areas for improvement, etc.)
Study: NCT04565015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC5107
Description: Intravenously infused at a dose of 300 - 900 mg per kg (of body weight) every 21 or 28 days for 12 months